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Synthesis of pentaﬂuorosulfanyl (SF5) containing aromatic amino acids
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A B S T R A C T
Herein, a series of aromatic pentaﬂuorosulfanyl (SF5) containing amino acids are reported. A Negishi cross-
coupling strategy utilising a catalyst system of Pd(dba)2 and SPhos aﬀorded the aforementioned SF5 amino acids
in yields between 32% and 42%. Two dipeptides utilising both the amine and carboxylic functionalities of the
synthesised SF5 containing amino acids were prepared, demonstrating their compatibility with common amide/
peptide coupling reagents and strategies.
1. Introduction
The synthesis of novel amino acids is an area of considerable in-
terest as it oﬀers a route to access not only previously inaccessible
natural products but also to modulate the properties of peptides [1–3].
Furthermore, the ability to include additional functionality (e.g. NMR
probes, handles for chemical modiﬁcation or bioconjugation) within
peptide sequences has led to increasing interest in the synthesis of
unusual amino acids in areas such as medicinal chemistry [4] and drug
discovery [5,6].
Fluorine atoms have been demonstrated to modulate the structure,
stability and activity of peptides [7]. For example, Meng and Kumar
demonstrated that introduction of ﬂuorine atoms into antimicrobial
peptides increased their bacteriostatic activity or improved their sta-
bility towards protease degredation [8]. Therefore, the ability for
peptide chemists to be able to readily access amino acid building blocks
containing ﬂuorine atoms is of the upmost importance.
The pentaﬂuorosulfanyl (SF5) functional group is a moiety which at
present is diﬃcult to introduce into peptide sequences even though it
has garnered attention across many research areas. The steric bulk and
electronics of the SF5 group can modify both the conformation and
chemical properties of a compound. This has led to the SF5 group being
utilised to develop new pharmaceuticals [9] and agrochemicals [10].
The SF5 group has also been used as a substitute for the tri-
ﬂuoromethyl (CF3) group [11], however their physical and chemical
properties diﬀer quite considerably [12]. For instance, the geometry,
the electron density proﬁle, chemical/thermal stability and volume of
the two groups are all very diﬀerent. In addition due to their steric and
electronic properties SF5 groups have also been investigated as re-
placements for tert-butyl [13], halogen [9] and nitro [14] functional-
ities.
There are a variety of ways to access alkyl [15–18] and aryl [19–24]
pentaﬂuorosulfanyl compounds. Despite the advances in the utility and
synthesis of SF5 building blocks, the ability to introduce them into
peptides has so far been limited [25]. To the best of our knowledge only
one previous synthesis of an SF5 amino acid has been disclosed. Welch
and co-workers reported a six step synthesis of an SF5 containing allyl
glycine derivative 3 and further elaborated the amino acid into a
heptapeptide (Scheme 1) [25].
In order to further explore the SF5 group in the ﬁeld of peptide
chemistry, we targeted the synthesis of pentaﬂuorosulfanyl phenylala-
nine derivatives. Herein, we report the ﬁrst synthesis of SF5 aromatic
amino acids utilising a Negishi cross-coupling as a key CeC bond
forming step.
2. Results and discussion
Negishi cross-coupling has been used to access a wide range of
amino acids previously within the literature [26,27]. Therefore to begin
with a halogenated amino acid precursor 4 was selected as one coupling
partner for our Negishi strategy. The two enantiomers of the benzyl
protected iodo cross-coupling partner were synthesised from the cor-
responding Boc protected serines as previously reported [28].
Next a Negishi cross-coupling reaction was carried out between
iodo-alanine 4S and commercially available 1-bromo-4-(penta-
ﬂuorosulfanyl)benzene. Iodo-alanine 4S was treated with 4 equivalents
of zinc in dry DMF. The formed alkyl zinc species was reacted with 1-
bromo-4-(pentaﬂuorosulfanyl)benzene as the other coupling partner.
The reaction was carried out with a tri(o-tolyl)phosphine (P(o-tol)3)
ligand (10mol%) and a Pd(dba)2 catalyst (3 mol%). This gave a dis-
appointing 8% yield of the desired cross-coupling product 6R (Table 1
Entry 1). When 1-bromo-3-(pentaﬂuorosulfanyl)benzene was employed
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a yield of 26% of compound 5R was obtained (Table 1 Entry 2). In an
attempt to improve these yields the (P(o-tol)3) ligand was switched for
SPhos. SPhos has been previously shown by Jackson and co-workers to
improve the yields of Negishi cross-coupled products in the reaction
between amido zinc species and aryl bromides [29].
The addition of SPhos showed a marked improvement in the yields
of the cross-coupled products. The yield of 6R was increased to 38%
(Table 1 Entry 3) and 5R was similarly increased to 35% (Table 1 Entry
4). The opposite enantiomer, 4R was also exposed to the SPhos/Pd
(dba)2 mediated conditions garnering the SF5 containing species 6S and
5S in 42% and 32% yield respectively (Table 1 Entries 5 and 6).
Compound 6S was successfully crystallised through vapour diﬀu-
sion of water and ethanol and a crystal structure was obtained (Fig. 1)
[30]. The structure obtained for 6S displayed an absolute conﬁguration
of S conﬁrming our stereochemical assignment.
In order to demonstrate the compatibility of 5 and 6 with amide
bond formation and in turn peptide synthesis we sought to form di-
peptides with both of these synthesised pentaﬂuorosulfanyl amino
acids. In addition, we hoped that our choice of orthogonal protecting
groups would mean that selective deprotection could be carried out
without degradation of the amino acids occurring.
Boc deprotection of 5R was carried out using standard TFA medi-
ated reaction conditions. The deprotected amino acid was reacted di-
rectly with BoceAlaeOH in the presence of PyBOP and N-methyl
morpholine (NMM). The amide bond forming reaction proceeded
smoothly to garner the desired dipeptide 8 in a 71% yield, over the two
steps (Scheme 2).
Next the benzyl protected amino acid 6R was deprotected through
hydrogenation with palladium on charcoal to give the corresponding
methyl ester 9, which was subsequently deprotected to the free car-
boxylic acid 10 using lithium hydroxide. This material was directly
coupled with BoceAlaeOH in the presence of PyBOP and NMM. This
reaction aﬀorded the dipeptide 11 in a 19% yield over 3 steps (Scheme
3).
3. Conclusion
We have demonstrated that SF5 containing aromatic amino acids
can be accessed through the Negishi cross-coupling of penta-
ﬂuorosulfanyl aryl bromides with amido alkyl iodide species. The use of
SPhos as a ligand for palladium helped to increase the yields for the
cross-couplings. This methodology is to the best of our knowledge only
the second disclosed route to an SF5 containing amino acid and the ﬁrst
to yield an aromatic SF5 amino acid. The synthesised aryl-SF5 amino
acids were shown to be compatible with standard amide/peptide bond
coupling reagents and de-protection strategies. We are now exploring
the application of the newly formed aromatic SF5 amino acids in larger
peptide sequences, as a means to modify their chemical and physical
properties.
Scheme 1. Previously accessed SF5 containing
amino acid, Welch and co-workers [25].
Table 1
Reaction optimisation of the key Negishi cross-coupling reaction.
Starting material Ligand Bromo-phenyl-SF5 Product Yield (%)a
P(o-tol)3 6R 8b
P(o-tol)3 5R 26b
SPhos 6R 38b
SPhos 5R 35b
SPhos 6S 42c
SPhos 5S 32c
a) Refers to the isolated yield following ﬂash column chromatography.
b) Reactions stirred at 50 °C for 5 h.
c) Reactions stirred at 50 °C for 3 h.
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4. Experimental
4.1. General
All starting materials and reagents were bought from commercial
sources and used as received. 1H NMR spectra were recorded at 400, 600
and 700MHz using Bruker Avance III, Varian VNMR(S)-600 and Varian
VNMR(S)-700 spectrometers. 13C NMR spectra were recorded at 100, 151
and 176MHz using Bruker Avance III, Varian VNMR(S)-600 and Varian
VNMR(S)-700 spectrometers. 19F NMR spectra were recorded at 376MHz
using a Bruker Avance III spectrometer. All coupling constants are reported
in Hertz (Hz). In cases where it was required 2D NMR techniques were used
to conﬁrm compound identity. Chemical shifts are reported in ppm and are
referenced to residual solvent peaks; CHCl3 (1H 7.26 ppm, 13C 77.0 ppm)
and DMSO (1H 2.50 ppm, 13C 39.5 ppm). Mass spectra were collected on a
Waters TQD mass spectrometer and accurate mass spectra were collected
on a Waters LCT Premier XE mass spectrometer. Optical rotations were
measured with a Jasco P-1020 polarimeter at room temperature.
4.2. General method for Negishi cross-coupling
Procedure A:
Zinc dust (0.193 g, 2.95mmol, 4.0 equiv.) was heated at 100 °C
under vacuum for 30min A catalytic amount of iodine in dry DMF
(0.5mL) was added and heated at 70 °C under argon for 20min. Iodo-
alanine derivative 4 (0.300 g, 0.74mmol, 1.0 equiv.) in dry DMF
(0.5mL) was added and the reaction mixture heated at 50 °C for 20min.
After this time the corresponding (Bromophenyl)sulfur pentaﬂuoride
(0.209 g, 0.74mmol, 1.0 equiv.), Pd(dba)2 (0.012 g, 3mol%) and P(o-
tol)3 (0.022 g, 0.073mmol, 0.1 equiv.) were added to the reaction
mixture and the reaction mixture stirred at 50 °C for 5 h followed by
24 h at rt. The crude material was puriﬁed directly by ﬂash column
chromatography (SiO2 100:0 to 0:100 hexane:DCM).
Procedure B:
The reaction was carried out in the same manner as described in
procedure A with P(o-tol)3 replaced by SPhos (0.030 g, 0.074mmol, 0.1
equiv.).
Fig. 1. Crystal structure of compound 6S.
Scheme 2. Formation of a dipeptide using SF5 amino acid 5R.
Scheme 3. Formation of a dipeptide using SF5 amino acid 8R.
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4.3. Synthesis of benzyl (R)-2-((tert-butoxycarbonyl)amino)-3-(3-(penta
ﬂuoro-l6-sulfanyl)phenyl)propanoate 5R
Compound 5R was synthesised according to the general Negishi
cross-coupling procedures
Procedure A: 0.091 g, 26%
Procedure B: 0.122 g, 35%
1H NMR (400MHz, CDCl3) δ 7.61 (d, J=8.5, 1H, ArH), 7.49 (s, 1H,
ArH), 7.39-7.35 (m, 3H, ArH), 7.32-7.27 (m, 3H, ArH), 7.15 (d, J=7.3,
1H, ArH), 5.14 (s, 2H, OCH2), 5.04 (d, J=7.1, 1H, NH), 4.65 (app. q,
J=5.8, 1H, Hα), 3.22 (dd, J=13.8, 5.8, 1H, Hβ), 3.10 (dd, J=13.8,
5.8, 1H, Hβ), 1.41 (s, 9H, Boc-CH3); 13C NMR (101MHz, CDCl3) δ
171.2, 155.0, 154.1, 154.1, 154.0, 137.4, 135.0, 132.7, 128.9, 128.83,
128.81, 128.7, 127.1, 124.8, 124.7, 124.7, 80.4, 67.6, 54.3, 38.3, 28.4;
19F -NMR (376MHz, CDCl3) 84.56 (quint., J=150.4, 1 F), 62.83 (d,
J=150.4, 4 F). HRMS ESI+ Calculated for [M+H]+
C21H25F5NO4S+=482.1424 Found=482.1443; α[ ]D27 = −18.76
(c= 1, CH2Cl2)
4.4. Synthesis of benzyl (R)-2-((tert-butoxycarbonyl)amino)-3-(4-
(pentaﬂuoro-l6-sulfanyl)phenyl)propanoate 6R
Compound 6R was synthesised according to the general Negishi
cross-coupling procedure
Procedure A: 0.030 g, 8%
Procedure B: 0.135 g, 38%
1H NMR (400MHz, CDCl3) δ 7.57 (d, J=8.3, 2H, ArH), 7.43 – 7.34
(m, 3H, ArH), 7.30 – 7.26 (m, 2H, ArH), 7.10 (d, J = 8.1, 2H, ArH),
5.19 (d, J=12.1, 1H, OCH2), 5.09 (d, J=12.1, 1H, OCH2), 5.03 (d,
J=8.1, 1H, NH), 4.65 (app. q, J=6.7, 1H, Hα), 3.17 (dd, J=13.8,
6.0, 1H, Hβ), 3.07 (dd, J=13.8, 6.0, 1H, β-Hβ), 1.41 (s, 9H, Boc-CH3);
13C NMR (101MHz, CDCl3) δ 171.3, 155.0, 152.8, 140.2, 135.0, 129.8,
128.9, 128.8, 126.2, 126.1, 126.1, 80.4, 67.6, 54.2, 38.1, 28.4; 19F NMR
(376MHz, CDCl3) δ 84.74 (quint., J=150.4, 1 F), 63.01 (d, J=150.4,
4 F). HRMS ESI+ Calculated for [M+H]+ C21H25F5NO4S+=482.1424
Found=482.1433; α[ ]D27 = −10.36 (c= 1, CH2Cl2).
4.5. Synthesis of benzyl (S)-2-((tert-butoxycarbonyl)amino)-3-(3-(penta
ﬂuoro-l6-sulfanyl)phenyl)propanoate 5S
Compound 5S was synthesised according to the general Negishi
cross-coupling procedure B with the following modiﬁcation. The reac-
tion was stirred for 3 h at 50 °C followed by 24 h at rt to give the pro-
duct in a 32% (0.225 g) yield.
1H NMR (400MHz, CDCl3) δ 7.61 (dd, J=8.2, 2.2, 1H, ArH), 7.50
(s, 1H, ArH), 7.40-7.35 (m, 3H, ArH), 7.34-7.28 (m, 3H, ArH), 7.16 (d,
J=7.6, 1H, ArH), 5.14 (s, 2H, OCH2), 5.10 (d, J=8.2, 1H, NH), 4.66
(app. q, J=6.5, 1H, Hα) 3.23 (dd, J=13.9, 6.0, 1H, Hβ), 3.11 (dd,
J=13.9, 6.0, 1H, Hβ), 1.42 (s, 9H, Boc-CH3); 13C NMR (101MHz,
CDCl3) δ 171.2, 155.0, 154.2, 154.1, 153.9, 137.4, 135.0, 132.6, 128.9,
128.8, 128.8, 128.7, 127.1, 124.7, 124.7, 124.7, 80.3, 67.5, 54.3, 38.2,
28.3; 19F NMR (376MHz, CDCl3) δ 84.60 (quint., J=149.8, 1 F), 62.84
(d, J=149.8, 4 F); HRMS ESI+ Calculated for [M+H]+
C21H25F5NO4S+=482.1424 Found= 482.1436; α[ ]D27 = +19.08
(c= 1, CH2Cl2).
4.6. Synthesis of benzyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-(penta
ﬂuoro-l6-sulfanyl)phenyl)propanoate 6S
Compound 6S was synthesised according to the general Negishi
cross-coupling procedure B with the following modiﬁcation. The reac-
tion was stirred for 3 h at 50 °C followed by 24 h at rt to give the pro-
duct in a 42% (0.300 g) yield.
1H NMR (400MHz, CDCl3) δ 7.57 (d, J=8.3, 2H, ArH), 7.39 – 7.34
(m, 3H, ArH), 7.30 – 7.26 (m, 2H, ArH), 7.10 (d, J=8.2, 2H, ArH),
5.19 (d, J = 12.1, 1H, OCH2), 5.09 (d, J=12.1, 1H, OCH2), 5.03 (d,
J=8.1, 1H, NH), 4.65 (m, 1H, Hα), 3.17 (dd, J = 13.8, 6.0, 1H, Hβ),
3.07 (dd, J = 13.8, 6.0, 1H, Hβ), 1.41 (s, 9H, Boc-CH3); 13C NMR
(101MHz, CDCl3) δ 171.3, 155.0, 152.8, 140.2, 135.0, 129.8, 128.9,
128.8, 126.2, 126.1, 126.1, 80.4, 67.6, 54.2, 38.1, 28.4; 19F NMR
(376MHz, CDCl3) δ 84.58 (quin., J =156.8 Hz, 1 F), 62.97 (d,
J=156.8 Hz, 4 F); HRMS ESI+ Calculated for [M+H]+
C21H25F5NO4S+=482.1424 Found= 482.1446; α[ ]D27 = +10.78
(c= 1, CH2Cl2).
Crystal data for 6S: C21H24F5NO4S, M=481.47, monoclinic, space
group P 21, a= 13.8424(11), b= 5.4800(5), c= 15.2791(12) Å,
β=113.218(3)°, U=1065.15(15) Å3, F(000)= 500.0, Z=2,
Dc= 1.501mg m−3, μ=0.224mm-1 (Mo-Kα, λ=0.71073 Å),
T= 120(1)K. 21,584 reﬂections were collected on a Bruker D8Venture
(Photon100 CMOS detector, Iμ(S)-microsource, focusing mirrors, shut-
terless mode, 1° ω-scan) diﬀractometer yielding 5393 unique data
(Rmerg= 0.0614). The structure was solved by direct method and re-
ﬁned by full-matrix least squares on F2 for all data using SHELXTL and
OLEX2 software [31,32]. All non-hydrogen atoms were reﬁned with
anisotropic displacement parameters; H-atoms were placed into calcu-
lated positions and reﬁned in riding mode. Final wR2(F2)= 0.1651 for
all data (385 reﬁned parameters), conventional R1(F)= 0.066 for 4374
reﬂections with I≥ 2σ, GOF=1.075. The absolute conﬁguration of the
compound has been established by measurements of anomalous dis-
persion eﬀects (Flack parameter (x)= 0.1(1), Hooft parameter
(y)= 0.07(4)). Crystallographic data for the structure have been de-
posited with the Cambridge Crystallographic Data Centre as supple-
mentary publication CCDC-1837505.
4.7. Synthesis of benzyl (R)-2-((S)-2-((tert-butoxycarbonyl)amino)
propanamido)-3-(3-(pentaﬂuoro-l6-sulfanyl)phenyl)propanoate 8
To a stirred solution of Boc-D-(3-SF5)-Phe-OBn (5R) (0.110 g,
0.23mmol) in DCM (4mL) was added TFA (4mL) and the resulting
solution was stirred at room temperature for 2 h. The reaction mixture
was concentrated under reduced pressure and any residual TFA was
removed by co-evaporation with ether. The recovered material was
suspended in DCM (2mL) and NMM (0.087 g, 0.86mmol, 0.08mL)
added, the resulting solution was stirred for 5min at rt. PyBOP (0.120 g,
0.23mmol) and BoceAlaeOH (0.044 g, 0.23mmol) dissolved in DCM
(2mL) were then added and the reaction mixture left to stir for 15 h at
rt. The reaction mixture was concentrated under reduced pressure and
puriﬁed via column chromatography (100:0 to 0:100, hexane/EtOAc).
Dipeptide 8 was aﬀorded as a cream solid in a 71% (0.090 g) yield over
2 steps.
1H NMR (400MHz, CDCl3) δ 7.61 (ddd, J=8.3, 2.3, 1.0, 1H, ArH),
7.47 (t, J=1.9, 1H, ArH), 7.40 – 7.34 (m, 3H, ArH), 7.34 – 7.27 (m,
3H, ArH), 7.18 (d, J=7.6, 1H, ArH), 6.72 (s, 1H, NH), 5.13 (app s, 2H,
Bn-CH2), 4.90 (app. q, J=6.1, 1H, Phe (3-SF5)-Hα), 4.84 (bs, 1H, NH),
4.16 (m, 1H, Ala-Hα), 3.23 (dd, J=14.0, 5.8, 1H, Phe (3-SF5)-Hβ), 3.16
(dd, J=14.0, 5.8, 1H Phe (3-SF5)-Hβ), 1.41 (s, 9H, Boc-CH3), 1.30 (d,
J=7.1, 3H, Ala- Hβ); 13C NMR (101MHz, CDCl3) δ 172.6, 170.8,
155.6, 154.3, 154.1, 154.0, 137.2, 134.9, 132.7, 129.0, 128.8, 128.6,
126.9, 126.9, 126.8, 124.8, 124.8, 124.7, 80.4, 67.7, 53.2, 50.1, 37.8,
29.8, 28.4, 18.2; 19F NMR (376MHz, CDCl3) δ 84.46 (quin., J=149.9,
1 F), 62.79 (d, J=149.9, 4 F); HRMS ESI+ Calculated for [M+H]+
C24H30F5N2O5S+=553.1796 Found = 553.1797.
4.8. Synthesis of methyl ((R)-2-((tert-butoxycarbonyl)amino)-3-(4-(penta
ﬂuoro-l6-sulfanyl)phenyl)propanoyl)-L-alaninate 11
To a mixture of Boc-D-(4-SF5)-Phe-OBn (6R) (0.075 g, 0.16mmol)
and Pd/C 10wt% under an inert atmosphere was added dry methanol
(10mL). The solution was stirred for 24 h under a positive pressure of
hydrogen. The solution was concentrated under reduced pressure and
the residue taken up in THF (1mL). The resulting solution was cooled to
0 °C before addition of a solution of LiOH (0.014 g, 2 equiv.) in water
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(0.5 mL), the reaction was stirred for 2 h at 0 °C. The reaction mixture
was then concentrated under reduced pressure. The remaining solution
was acidiﬁed to pH≈ 3 with an aqueous solution of citric acid (10%w/
v). The solution was extracted with EtOAc (3 x 5mL). The combined
organic layers were washed with brine (5mL), dried over MgSO4 and
concentrated under reduced pressure. The recovered oil was dissolved
in DCM (2mL) and PyBOP (0.084 g, 1 equiv.) added, the resulting so-
lution was stirred at room temperature. In a separate ﬂask, NH2-Ala-
OMe.HCl (0.023 g, 1 equiv.) was dissolved in DCM (2mL), NMM
(0.06mL, 3 equiv.) added and the resulting solution stirred for 5min.
The two solutions were mixed together and stirred at room temperature
for 86 h. The reaction mixture was concentrated under reduced pressure
and the residue puriﬁed via column chromatography (100% hexane to
100% EtOAc) to aﬀord dipeptide 11 as a cream solid in a 19% (0.015 g)
yield over 3 steps.
1H NMR (400MHz, CDCl3) δ 7.68 (d, J=8.4, 2H, ArH), 7.31 (d,
J=8.4, 2H, ArH), 6.45 (d, J=7.4, 1H, NH), 4.95 (br s, 1H, NH), 4.52
(app t, J=7.2, 1H, Ala-Hα), 4.41 (br s, 1H, SF5-Phe-Hα), 3.74 (s, 3H,
OCH3), 3.19 (dd, J=14.0, 7.0, 1H, SF5-Phe-Hβ), 3.05 (dd, J=14.0,
7.0, 1H, SF5-Phe-Hβ), 1.39 (s, 9H, CH3), 1.31 (d, J=7.1, 3H, Ala-Hβ);
13C NMR (176MHz, CDCl3) δ 172.89, 170.00, 140.81, 129.67, 126.15,
55.21, 52.53, 48.02, 37.83, 29.67, 28.16, 18.11. 19F NMR (376MHz,
CDCl3) δ 84.58 (quin., J= 156.8, 1 F), 62.97 (d, J=156.8, 4 F). HRMS
ESI+ Calculated for [M+H]+ C18H35F5N2O5S+=477.1490
Found=477.1483.
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